Aduro Biotech — Chinook Therapeutics — Technical Presentation (June 2023)
6 slides from Aduro Biotech's technical presentation, Jun 12, 2023
Slide 1: Immunoglobulins, Combined Cohorts
Immunoglobulins, Combined Cohorts % Change from baseline (Mean + SE) 10% 0% 10% IgA -eGd-lgA1 -elgG -eIgM -20% -30% 40% -50% 60% -70% 80% -90% 4 12 24 40 52 76 100 Ga-l 3534 26 18 7 7 {35 35 34# 30 23 16 8 6 *IgA n=33 at week 12
Slide 2: IgA
IgA % Change from Basel 10% Data cut-off May 8, 2023 10% -30% @ (Mean + SE) -*Cohort 1 Cohort 2 50% -70% 90% Wk 4 12 24 40 52 76 100 Co1, 8.8 5 te 8 6 Co2,n= 27 2 2 15 9
Slide 3: Gd-IgA1
Gd-IgA1 % Change from Baseline (Mean + SE) 10% Data cut-off March 1, 2023 -10% -30% ~50% -70% -90% Wk 4 12 24 40 52 76 100 8 7 a 3 10
Slide 4: IgM
IgM % Change from Baseline (Mean + SE) 10% Data cut-off May 8, 2023 10% -*-Cohort 1 =e — Cohort 2 50% -70% -90% Wk 4 12 24 4052 76 100 Coin= 8 8 5 8 7 8 6 Co2,n= 27 26 25 ar)
Slide 5: 24-hour UPCR
24-hour UPCR • Zigakibart treatment resulted in sustained, clinically meaningful proteinuria reductions in patients with IgAN across a wide range of baseline proteinuria levels. • In the combined Cohorts 1 and 2, zigakibart demonstrated mean reductions in 24-hour urine protein creatinine ratio (UPCR
Slide 6: Overviews of the phase BEYOND and phase ASSIST trials are also being presented
Overviews of the phase 3 BEYOND and phase 2 ASSIST trials are also being presented as focused oral presentations (digital poster with 3-minute presentation) on Friday, June 16, 2023. A moderated oral presentation (6-slide presentation) on research regarding the impact of maladaptive tubular epitheli
Chinook Therapeutics — Technical Presentation (June 2023) on 6ix